Investors & Media Events & Presentations Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition 06.06.2018 8:00 AM EDT Click here for webcast
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition 06.06.2018 8:00 AM EDT Click here for webcast
